Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard-of-care for patients with advanced non-small cell lung cancer (aNSCLC) and programmed cell death-ligand 1 (PD-L1) expression ≥50%. METHODS: A retrospective cohort study was conducted using the US de-identified electronic health record-deri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Wenzhen, Wu, Ning, Jalbert, Jessica J, Quek, Ruben G W, Liu, Jinjie, Rietschel, Petra, Pouliot, Jean-Francois, Harnett, James, Hsu, Melinda Laine, Feliciano, Josephine L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675996/
https://www.ncbi.nlm.nih.gov/pubmed/36415537
http://dx.doi.org/10.2147/CMAR.S376510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675996/
https://www.ncbi.nlm.nih.gov/pubmed/36415537
http://dx.doi.org/10.2147/CMAR.S376510

Ejemplares similares